A new sperm sorting technique, which can separate faster moving from slower sperm, has recently been described by investigators from the University of California, Irvine (UCI) and San Diego (USCD) (Shao et al., Methods Cell Biol 2007; 82:601-627) . It involves laser trapping in the near infrared regime, a noninvasive and microfluid-compatible biomedical technology.
The heavier X sperm usually is slower moving than the lighter Y-sperm and this technology, therefore, also lends itself to sperm sorting and sex selection. A potential, at least theoretical, advantage over MICROSORT would be the absence of need for any nuclear-bound fluorescence dye.
Many will recall the controversy that arose over the original MICROSORT patent application. It will be interesting to see whether the manuscript, describing this new technique, will also as rapidly be followed by a patent application.
What's new in the UK?
While the politically correct single-embryo transfer story continues to make headlines in Europe (the US, of course, is trying hard to catch up), it now turns out that British women with fertility problems are not that different from US women, after all; they, too, if given the chance, would rather take the risk of multiples than face not conceiving at all (Scottland et al., BJOG 2007; 114:977-983) . Reiterating the fact that this discussion has become ideologically political, and has lost scientific integrity, the journal's editor-in-chief, Prof. Philip Steer, is quoted as accusing women, conceiving via IVF as showing limited appreciation regarding the risks involved with multiple births for both mother and child (Alisia Taylor, Progress Educational Trust, August 26, 2007) .
And where is the data in support of such a statement? Infertility patients are, of course, amongst the best educated consumers in medicine. In the absence of intellectual arguments, nothing is easier than to call the other side uneducated, or let's say it bluntly,-stupid. Politicians do this all the time. Physicians should know better! Wow, what a surprise! IVF pregnancy outcomes in the UK are better in private clinics than in clinics run by the National Health Service, a BBC investigation recently was reported to have found. Did anybody really expect anything else?
The funny thing, of course, is that we all know that such an outcome is to be expected (listen carefully proponents of a national health care service); yet, at the same time, we also know that the whole concept of comparing IVF outcomes between IVF centers is pure nonsense. It cannot be done reliably, and is subject to blatant manipulation through patient selection. Sometimes it doesn't, however, take a study to know medical facts! And the conclusion therefore is: The BBC, of course, doesn't know how to interpret medical data; yet, sometimes, even the BBC can be correct.
The latest business opportunity in the UK: bartering for IVF services: Give me your sperm and I'll give you free fertility treatments. And what brought us to this?
It all started with the notion that offspring from sperm donations should be entitled to know their genetic fathers. Maybe a good idea, maybe not; nobody, however, seriously considered the consequences. The UK now suffers from a nationwide shortage of donor sperm. A new law, revealing the identity of semen donors is not the only reason for this shortage. Other causes, like for example the legal prohibition to pay donors, may also play roles.
The combined consequences now are, however, what have to be considered coerced, semen donations. While patients in the UK are not allowed to pay donors, IVF programs are permitted to discount fees in return for such donations. Now that makes sense; doesn't it! Hopefully, everybody sees here yet another formidable example for the wisdom of legislative interventions into the practice of medicine?
What is wrong with our medical meetings?
Wouldn't you agree that medical meetings in our specialty no longer are what they once used to be? Somehow, the air seems to have escaped from the tires, and what's left is not very appetizing. Nobody should be surprised if attendance continues to decline because there are increasingly less reasons to attend.
Motivations for attendance, of course, vary. While for some having a few days off from their routine, or socializing with old friends, may be good enough reasons, most of us need a little more than that. The more scientifically minded amongst us usually travel to congresses (in this order) because (1) we were invited; (2) we want to present our new data; and (3) we hope to learn something new and exiting ahead of publication. Our more clinically inclined colleagues share our interest in new data, even if their desire for new clinical pearls may be more clinically oriented. They often also take advantage of postgraduate satellite offerings.
Postgraduate offerings have become stale. Have you recently seen any interesting new ideas for such events?
The bureaucracy surrounding them has become mind blowing: conflict statement, disclosure forms and, probably soon, FBI background checks.
Have you in recent years heard about any scientific breakthroughs? Remember the buzz when ICSI was first presented? Yes, stem cells are exiting, but the good stem cell science is not covered in reproductive endocrinology meetings. We only dabble and supply cells.
Abstract submissions are also no longer what they once used to be. Nowadays, even at the nation's most prestigious meeting, committees of as few as two members may decide on acceptance, and select abstracts from one of the referee's own group for almost half of the section's assigned oral presentation spots. Everywhere else this, of course, would be seen as a blatant conflict of interest. Here, voting for ones own submissions is just business as usual.
The grapevine tells us that there is simply not enough money around anymore. It is true that pharmaceutical company sponsorships seem to have declined in our area of specialty. But one has to ask, why the interest of the pharmaceutical industry has been waning, when the same doesn't happen in cardiology, oncology or other medical specialties?
Simple questions, of course, do not always have simple answers. It is common knowledge that, in contrast to the above noted areas of medicine, the market for pharmaceutical sales in infertility practice has shrunk in recent years and is predicted to remain suppressed for the foreseeable future. The principle reasons are changes in patient demographics: as baby boomers are moving out of their childbearing years, the next generations of potential mothers is just numerically smaller.
Paradoxically, neither the profession, nor the pharmaceutical industry have been doing much about this development. Even though women above age 40 now represent the most rapidly growing age group having children, scientifically the aging ovary has attracted only very little attention. Clinically, the sentiment is, of course, to stay away from women with severely diminished ovarian reserve because their obviously limited outcomes could adversely affect program rates. As a consequence, the one, principal, remaining open frontier in infertility, the aging ovary, has seen practically no improvement in outcome over the last 10 or 15 years.
Instead, the topics of the day are single embryo transfer (really applicable to what percentage of IVF cycles?); fertility preservation (and what are the numbers here?) and mild ovarian stimulation (ever noticed the pregnancy rates?), all, of course, great strategies to make up for lost market volume.
The answer is always the same: We have discovered the enemy; it is us!
